Dyslipidemic drugs in metabolic syndrome

INTRODUCTION: Metabolic syndrome predisposes to diabetes and atherosclerotic vascular disease. Statins reduce cardiovascular events, so all metabolic syndrome patients should be evaluated for dyslipidemia. Many patients fail to achieve lipid goals with statin monotherapy. Co-administration of ezetim...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqi, Sheelu S., Misbahuddin, Ahmad, Farida, Rahman, Syed Z., Khan, Asad U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712379/
https://www.ncbi.nlm.nih.gov/pubmed/23869305
http://dx.doi.org/10.4103/2230-8210.111644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712379/
https://www.ncbi.nlm.nih.gov/pubmed/23869305
http://dx.doi.org/10.4103/2230-8210.111644

Ejemplares similares